Sponsor
Borstkanker Onderzoek Groep
Clinical research sponsor
Clinical trials
24 shownSEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)NCT05392608 · lead sponsor · 2022-06-02
ACTIVE_NOT_RECRUITINGTAS102 in Patients With ER-positive, HER2-negative Advanced Breast CancerNCT04489173 · lead sponsor · 2020-09-25
COMPLETEDTailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.NCT03283384 · lead sponsor · 2019-06-15
ACTIVE_NOT_RECRUITINGImage-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 StudyNCT03820063 · lead sponsor · 2019-02-27
ACTIVE_NOT_RECRUITINGStudy to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast CancerNCT03532087 · lead sponsor · 2018-02-01
WITHDRAWNEndocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast CancerNCT03425838 · lead sponsor · 2017-11-09
ACTIVE_NOT_RECRUITING8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast CancerNCT01935492 · lead sponsor · 2010-11-01
COMPLETEDNeo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer PatientsNCT01099436 · lead sponsor · 2010-04-01
COMPLETEDPostoperative Re-irradiaTion With and Without HYPERthermia, or Surgery Only: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast CancerNCT06452485 · collaborator · 2024-02-01
RECRUITINGElacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · collaborator · 2023-12-15
RECRUITINGDESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic TherapyNCT05416164 · collaborator · 2022-10-07
RECRUITINGMitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side EffectsNCT06424054 · collaborator · 2025-06-01
NOT_YET_RECRUITINGFasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast CancerNCT05503108 · collaborator · 2023-03-17
SUSPENDEDEffectiveness of Personalized Surveillance and Aftercare for Breast CancerNCT05975437 · collaborator · 2023-03-06
ENROLLING_BY_INVITATIONManagement of Low-risk (Grade I and II) DCISNCT02492607 · collaborator · 2017-02-13
ACTIVE_NOT_RECRUITINGOmitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving TherapyNCT02271828 · collaborator · 2015-05-18
COMPLETEDOmitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a MastectomyNCT02112682 · collaborator · 2014-06-01
TERMINATEDAnalysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneNCT02109913 · collaborator · 2014-03-01
UNKNOWNDIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast CancerNCT02126449 · collaborator · 2014-02-01
COMPLETEDNeoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2NCT01996267 · collaborator · 2013-12-01
ACTIVE_NOT_RECRUITINGTriple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast CancerNCT01898117 · collaborator · 2013-07-01
ACTIVE_NOT_RECRUITINGSystemic Therapy With or Without Upfront Surgery in Metastatic Breast CancerNCT01392586 · collaborator · 2012-02-01
TERMINATEDMale Breast Cancer: Understanding the Biology for Improved Patient CareNCT01101425 · collaborator · 2010-12-01
ACTIVE_NOT_RECRUITINGRadiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the BreastNCT00470236 · collaborator · 2007-06-01
UNKNOWNSponsor roles
collaborator16
lead sponsor8
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.